Antiphospholipid Syndrome: Pathogenesis

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 945-965

  Atsumi, Tatsuya ^a   Amengual, Olga ^a   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872368872     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10050-6     Document Type: Chapter

References (205)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Hughes G.R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983, 287:1088-1089.
3. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002, 46:1019-1027.
4. Wassermann A., Neisser A., Bruck C. Eine serodiagnostishe reaction bei syphilis. Dtsch Med Wochenschr 1906, 32:745-746.
5. Pangborn M.C. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 1941, 48:484-486.
6. Mueller J.F., Ratnoff O., Henile R.W. Observations on the characteristics of an unusual circulating anticoagulant. J Lab Clin Med 1951, 38:254-261.
7. Haserick J.R., Long R. Systemic lupus erythematosus preceded by false positive test for syphilis: Presentation of five cases. Ann Intern Med 1951, 37:559-565.
8. Moore J.E., Lutz W.B. The natural history of systemic lupus erythematosus: An approach to its study through chronic biological false positive reactors. J Chronic Dis 1955, 1:297-316.
9. Moore J.E., Mohr C.F. Biologically false positive serologic test for syphilis: Type, incidence, and cause. JAMA 1952, 150:467-473.
10. Conley C.L., Hartman R.C.A. A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated lupus erythematosus. J Clin Invest 1952, 31:621-622.
11. Laurell A.B., Nilsson I.M. Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction: A study in two cases. J Lab Clin Med 1957, 49:694-707.
12. Feinstein D.I., Rapaport S.I. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972, 1:75-95.
13. Harris E.N., Gharavi A.E., Boey M.L., Patel B.M., Mackworth-Young C.G., Loizou S., et al. Anti-cardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2:1211-1214.
14. Koike T., Sueishi M., Funaki H., Tomioka H., Yoshida S. Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984, 56:193-199.
15. Harris E.N., Gharavi A.E., Loizou S., Derue G., Chan J.K., Patel B.M., et al. Cross-reactivity of antiphospholipid antibodies. J Clin Lab Immunol 1985, 16:1-6.
16. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990, 87:4120-4124.
17. Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990, 335:952-953.
18. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990, 336:177-178.
19. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994, 179:457-462.
20. Bevers E.M., Galli M., Barbui T., Comfurius P., Zwaal R.F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991, 66:629-632.
21. Oosting J.D., Derksen R.H.W.M., Bobbink I.W.G., Hackeng T.M., Bouma B.N., de Groot P.G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?. Blood 1993, 81:2618-2625.
22. Sugi T., McIntyre J.A. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995, 86:3083-3089.
23. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
24. Devaux P.F. Static and dynamic lipid asymmetry in cell membranes. Biochemistry 1991, 30:1163-1173.
25. Connor J., Pak C.H., Zwaal R.F., Schroit A.J. Bidirectional transbilayer movement of phospholipid analogs in human red blood cells. Evidence for an ATP-dependent and protein-mediated process. J Biol Chem 1992, 267:19412-19417.
26. Zhou Q., Zhao J., Stout J.G., Luhm R.A., Wiedmer T., Sims P.J. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem 1997, 272:18240-18244.
27. Zwaal R.F., Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132.
28. Mann K.G., Nesheim M.E., Church W.R., Haley P., Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complex. Blood 1990, 76:1-16.
29. Wiedmer T., Zhou Q., Kwoh D.Y., Sims P.J. Identification of three new members of the phospholipid scramblase gene family. Biochim Biophys Acta 2000, 1467:244-253.
30. 2-glycoprotein I. Proc Natl Acad Sci USA 1984, 81:3640-3644.
31. Schultze H.E., Heide K., Haput H. Uber ein bisher ubekanntes niedermolekulars β2-Globulin des Humanserums. Naturwissenschaften 1961, 48:719.
32. 2-GPI in alternation anticardiolipin binding. Int Immunol 1991, 3:1217-1221.
33. Steinkasserer A., Estaller C., Weiss E.H., Sim R.B., Day A.J. Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J 1991, 277:387-391.
34. Bork P., Downing A.K., Kieffer B., Campbell I.D. Structure and distribution of modules in extracellular proteins. Q Rev Biophys 1996, 29:119-167.
35. 2-glycoprotein I. FEBS Lett 1992, 313:193-197.
36. Sheng Y., Sali A., Herzog H., Lahnstein J., Krilis S.A. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996, 157:3744-3751.
37. Sanghera D.K., Wagenknecht D.R., McIntyre J.A., Kamboh M.I. Identification of structural mutations in the fifth domain of apolipoprotein H (beta 2-glycoprotein I) which affect phospholipid binding. Hum Mol Genet 1997, 6:311-316.
38. Bouma B., de Groot P.G., van den Elsen J.M., Ravelli R.B., Schouten A., Simmelink M.J., et al. Adhesion mechanism of human β(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999, 18:5166-5174.
39. 2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999, 18:6228-6239.
40. Hoshino M., Hagihara Y., Nishii I., Yamazaki T., Kato H., Goto Y. Identification of the phospholipid-binding site of human beta (2)-glycoprotein I domain V by heteronuclear magnetic resonance. J Mol Biol 2000, 304:927-939.
41. Nakaya Y., Schaefer E.J., Brewer H.B. Activation of human post heparin lipoprotein lipase by apolipoprotein H (beta 2-glycoprotein I). Biochem Biophys Res Commun 1980, 95:1168-1172.
42. Wurm H., Beubler E., Polz E., Holasek A., Kostner G. Studies on the possible function of beta 2-glycoprotein-I: Influence in the triglyceride metabolism in the rat. Metabolism 1982, 31:484-486.
43. Kobayashi K., Matsuura E., Liu Q., Furukawa J., Kaihara K., Inagaki J., et al. A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001, 42:697-709.
44. Manfredi A.A., Rovere P., Galati G., Heltai S., Bozzolo E., Soldini L., et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998, 41:205-214.
45. 2-glycoprotein I. Arthritis Rheum 1998, 41:215-223.
46. 2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993, 70:342-345.
47. Schousboe I., Rasmussen M.S. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I. Thromb Haemost 1995, 73:798-804.
48. Nimpf J., Wurm H., Kostner G.M. Beta(2)-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987, 63:109-114.
49. 2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999, 42:167-174.
50. Steinkasserer A., Dorner C., Wurzner R., Sim R.B. Human beta 2-glycoprotein I: Molecular analysis of DNA and amino acid polymorphism. Hum Genet 1993, 91:401-402.
51. 2-glycoprotein I) protein polymorphism. Hum Genet 1997, 100:57-62.
52. 2-glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 1999, 42:1189-1193.
53. Yasuda S., Tustsumi A., Chiba H., Yanai H., Miyoshi Y., Takeuchi R., et al. Beta(2)-glycoprotein I deficiency: Prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000, 152:337-346.
54. Takeuchi R., Atsumi T., Ieko M., Takeya H., Yasuda S., Ichikawa K., et al. Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood 2000, 96:1594-1595.
55. Gushiken F.C., Arnett F.C., Thiagarajan P. Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of beta(2)-glycoprotein I. Am J Hematol 2000, 65:160-165.
56. 2-glycoprotein I null mice. J Biol Chem 2001, 276:13817-13821.
57. 2-glycoprotein I: Effects of specific cleavage between Lys77 and Thr78. J Biochem 1997, 121:128-137.
58. 2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998, 91:4173-4179.
59. 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994, 152:653-659.
60. 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993, 90:2141-2145.
61. Matsuura E., Inagaki J., Kasahara H., Yamamoto D., Atsumi T., Kobayashi K., et al. Proteolytic cleavage of beta(2)-glycoprotein I: Reduction of antigenicity and the structural relationship. Int Immunol 2000, 12:1183-1192.
62. 2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999, 81:87-95.
63. Itoh Y., Inuzuka K., Kohno I., Wada H., Shiku H., Ohkura N., et al. Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: Measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem 2000, 128:1017-1024.
64. 2-glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004, 103:3766-3772.
65. 2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property. Blood 2009, 114:2553-2559.
66. 2-glycoprotein I and preserved during species' evolution. J Immunol 1996, 157:5732-5738.
67. Koike T., Matsuura E. What is the "true" antigen for anticardiolipin antibodies?. Lancet 1991, 337:671-672.
68. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Suzuki T., Yoshida S., et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992, 148:3885-3891.
69. 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992, 1:75-81.
70. 2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a Baculovirus system. Blood 1996, 87:3262-3270.
71. 2GPI in antibody binding. J Immunol 1998, 150:3917-3923.
72. Iverson G.M., Reddel S., Victoria E.J., Cockerill K.A., Wang Y.X., Marti-Renom M.A., et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002, 169:7097-7103.
73. 2-glycoprotein I. Thromb Haemost 2001, 86:590-595.
74. 2-glycoprotein I interaction. J Autoimmun 2000, 15:97-100.
75. de Laat B., Derksen R.H., Urbanus R.T., de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005, 105:1540-1545.
76. Ioannou Y., Pericleous C., Giles I., Latchman D.S., Isenberg D.A., Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: Mutation studies including residues R39 to R43. Arthritis Rheum 2007, 56:280-290.
77. 2-glycoprotein I auto-antibodies. Int Immunol 2005, 17:1533-1542.
78. 2-glycoprotein I. Arthritis Rheum 1994, 37:1453-1461.
79. 2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome. Rheumatology 1999, 38:721-723.
80. 2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum 1999, 42:1655-1661.
81. 2-glycoprotein I variant. Arthritis Rheum 2005, 52:212-218.
82. Yoshida H., Fujiwara H., Fujiwara T., Ikehara S., Hamashima Y. Quantitative analysis of myocardial infarction in (NZW × BXSB) F1 hybrid mice with systemic lupus erythematosus and small coronary artery disease. Am J Pathol 1987, 129:477-485.
83. Hashimoto Y., Kawamura M., Ichikawa K., Suzuki T., Sumida T., Yoshida S., et al. Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992, 149:1063-1068.
84. Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., et al. Immunization with anticardiolipin cofactor (β-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994, 7:441-455.
85. Kouts S., Wang M.X., Adelstein S., Krilis S.A. Immunization of a rabbit with beta 2-glycoprotein I induces charge-dependent cross-reactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies. J Immonol 1995, 155:958-966.
86. 2 glycoprotein I and human immunoglobulin G antiphospholipid antibodies. Circulation 1996, 94:1746-1751.
87. 2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000, 43:65-75.
88. 2-glycoprotein I in patients with antiphospholipid syndrome: Preferential recognition of the major phospholipid-binding site. Blood 2001, 98:1889-1896.
89. Kuwana M., Matsuura E., Kobayashi K., Okazaki Y., Kaburaki J., Ikeda Y., et al. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005, 105:1552-1557.
90. Yamaguchi Y., Seta N., Kaburaki J., Kobayashi K., Matsuura E., Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007, 110:4312-4318.
91. Bowie E.J.W., Thompson J.H., Pascuzzi C.A. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963, 62:416.
92. Thiagarajan P., Shapiro S.S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980, 66:397-405.
93. Yin E.T., Gaston L.W. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Haemost 1965, 14:88-115.
94. Exner T., Rickard K.A., Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978, 40:143-151.
95. Oosting J.D., Derksen R.H., Entjes H.T., Bouma B.N., de Groot P.G. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992, 67:499-502.
96. 2-glycoprotein I. J Clin Invest 1992, 90:1100-1104.
97. 2GPI binding to phospholipids. J Clin Invest 1997, 99:2260-2268.
98. Arnout J., Vanrusselt M., Wittevrongel C., Vermylen J. Monoclonal antibodies against beta-2-glycoprotein I: Use as reference material for lupus anticoagulant tests. Thromb Haemost 1998, 79:955-958.
99. 2-glycoprotein I binding to phospholipid membranes. Thromb Haemost 1998, 80:610-614.
100. 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996, 35:13833-13842.
101. Arnout J., Wittevrongel C., Vanrusselt M., Hoylaerts M., Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998, 79:79-86.
102. Loeliger A. Prothrombin as a co-factor of the circulating anticoagulant in systemic lupus erythematosus?. Thromb Diath Haemorrh 1959, 3:237-256.
103. Rapaport S.I., Ames S.B., Duvall B.J. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 1960, 15:212-217.
104. Rao L.V.M., Hoang A.D., Rapaport S.I. Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb Haemost 1995, 73:668-674.
105. Chow B.K., Ting V., Tufaro F., MacGillivray R.T. Characterization of a novel liver-specific enhancer in the human prothrombin gene. J Biol Chem 1991, 1991:18927-18933.
106. Bajaj S.P., Rapaport S.I., Fierer D.S., Herbst K.D., Schwartz D.B. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983, 61:684-692.
107. Edson J.R., Vogt J.M., Hasegawa D.K. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 1984, 1984(64):807-816.
108. Fleck R.A., Rapaport S.I., Rao L.V.M. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988, 72:512-519.
109. Pengo V., Biasiolo A., Brocco T., Tonetto S., Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996, 75. 721-714.
110. Galli M., Beretta G., Daldossi M., Bevers E.M., Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997, 77:486-491.
111. Atsumi T., Ieko M., Bertolaccini M.L., Ichikawa K., Tsutsumi A., Matsuura E., et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000, 43:1982-1993.
112. Wu J.R., Lentz B.R. Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acidic lipid membranes. Thromb Haemost 1994, 71:596-604.
113. McDonald J.F., Shah A.M., Schwalbe R.A., Kisiel W., Dahlback B., Nelsestuen G.L. Comparison of naturally occurring vitamin K-dependent proteins: Correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997, 36:5120-5127.
114. 2-glycoprotein I or prothrombin. Clin Immunol 2004, 112:150-160.
115. Rao L.V., Hoang A.D., Rapaport S.I. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996, 88:4173-4182.
116. Akimoto T., Akama T., Kono I., Sumida T. Relationship between clinical features and binding domains of anti-prothrombin autoantibodies in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 1999, 8:761-766.
117. Pierangeli S.S., Goldsmith G.H., Branch D.W., Harris E.N. Antiphospholipid antibody: Functional specificity for inhibition of prothrombin activation by the prothrombinase complex. Br J Haematol 1997, 97:768-774.
118. Simmelink M.J., Horbach D.A., Derksen R.H., Meijers J.C., Bevers E.M., Willems G.M., et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001, 113:621-629.
119. 2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998, 91:1999-2004.
120. Sakai Y., Atsumi T., Ieko M., Amengual O., Furukawa S., Furusaki A., et al. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum 2009, 60:2457-2467.
121. Sanmarco M., Gayet S., Alessi M.C., Audrain M., de Maistre E., Gris J.C., et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on Antiphospholipid Antibodies. Thromb Haemost 2007, 97:949-954.
122. Bertolaccini M.L., Roch B., Amengual O., Atsumi T., Khamashta M.A., Hughes G.R.V. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol 1998, 37:1229-1232.
123. Sugi T., Mclntyre J.A. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996, 76:354-360.
124. McIntyre J.A., Wagenknecht D.R. Anti-phosphatidylethanolamine (aPE) antibodies: A survey. J Autoimmun 2000, 15:185-193.
125. Yamada H., Atsumi T., Kobashi G., Ota C., Kato E.H., Tsuruga N., et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009, 79:188-195.
126. Jone D.W., Nicholls P.J., Donohoe S., Gallimore M.J., Winter M. Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. Thromb Haemost 2002, 87:426-430.
127. Bertolaccini M.L., Mepani K., Sanna G., Hughes G.R., Khamashta M.A. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis 2007, 66:533-536.
128. Cariou R., Tobelem G., Bellucci S., Soria J., Soria C., Maclouf J., et al. Effect of lupus anticoagulant on antithrombotic properties of endothelial cells-Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988, 60:54-58.
129. Marciniak E., Romond E.H. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989, 71:2426-2432.
130. Malia R.G., Kitchen S., Greaves M., Preston F.E. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990, 76:101-107.
131. Borrell M., Sala N., de Castellarnau C., Lopez S., Gari M., Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992, 68:101-107.
132. 2-GPI): A possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 1998, 112:325-333.
133. Galli M., Willems G.M., Rosing J., Janssen R.M., Govers-Riemslag J.W., Comfurius P., et al. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005, 129:240-247.
134. Field S.L., Chesterman C.N., Hogg P.J. Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies. Thromb Haemost 2000, 84:1132-1133.
135. Ames P.R., Tommasino C., Iannaccone L., Brillante M., Cimino R., Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies-A crucial role for acquired free protein S deficiency. Thromb Haemost 1996, 76:190-194.
136. Ginsberg J., Demers C., Brill-Edwards P., Bona R., Johnston M., Wong A., et al. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995, 98:379-383.
137. McColl M.D., Deans A., Maclean P., Tait R.C., Greer I.A., Walker I.D. Plasma protein Z deficiency is common in women with antiphospholipid antibodies. Br J Haematol 2003, 20:913-914.
138. Pardos-Gea J., Ordi-Ros J., Serrano S., Balada E., Nicolau I., Vilardell M. Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis. Thromb Res 2008, 121:727-734.
139. Forastiero R.R., Martinuzzo M.E., Lu L., Broze G.J. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 2003, 1:1764-1770.
140. Shi T., Iverson G.M., Qi J.C., Cockerill K.A., Linnik M.D., Konecny P., et al. Beta 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci USA 2004, 101:3939-3944.
141. 2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum 2007, 56:605-613.
142. Shibata S., Harpel P.C., Gharavi A., Rand J., Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994, 83:2532-2540.
143. Jurado M., Paramo J.A., Gutierrez-Pimentel M., Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 1992, 68:516-520.
144. Francis R.B., McGehee J.A., Feinstein D.I. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemost 1988, 59:412-414.
145. Keeling D.M., Campbell S.J., Mackie I.J., Machin S.J., Isenberg D.A. The fibrinolytic response to venous occlusion and the natural anticoagulant in patients with antiphospholipid syndrome both with and without systemic lupus erythematosus. Br J Haematol 1991, 77:354-359.
146. Cugno M., Cabibbe M., Galli M., Meroni P.L., Caccia S., Russo R., et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: Evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004, 103:2121-2126.
147. Sugi T., Makino T. Autoantibodies to contact proteins in patients with recurrent pregnancy losses. J Reprod Immunol 2002, 53:269-277.
148. 2 glycoprotein I autoantibodies: Possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002, 119:781-788.
149. Carmona F., Lazaro I., Reverter J.C., Tassies D., Font J., Cervera R., et al. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. Am J Obstet Gynecol 2006, 194:457-465.
150. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachman R.L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991, 266:2459-2465.
151. Atsumi T., Khamashta M.A., Andujar C., Leandro M.J., Amengual O., Ames P.R., et al. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998, 25:69-73.
152. Yamazaki M., Asakura H., Jokaji H., Saito M., Uotani C., Kumabashiri I., et al. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 1994, 71:424-427.
153. Simantov R., LaSala J.M., Lo S.K., Gharavi A.E., Sammaritano L.R., Salmon J.E., et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995, 96:2211-2219.
154. Pierangeli S.S., Espinola R.G., Liu X., Harris E.N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001, 88:245-250.
155. Del Papa N., Sheng Y.H., Raschi E., Kandiah D.A., Tincani A., Khamashta M.A., et al. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol 1998, 160:5572-5578.
156. Kornberg A., Blank M., Kaufman S., Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994, 153:1328-1332.
157. Amengual O., Atsumi T., Khamashta M.A., Hughes G.R.V. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998, 79:276-281.
158. Branch D.W., Rodgers G.M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993, 168:206-210.
159. Atsumi T., Khamashta M.A., Haworth R.S., Brooks G., Amengual O., Ichikawa K., et al. Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. Arthritis Rheum 1998, 41:800-807.
160. Zhao Y., Rumold R., Zhu M., Zhou D., Ahmed A.E., Le D.T., et al. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 1999, 42:2132-2138.
161. Vega-Ostertag M., Liu X., Kwan-Ki H., Chen P., Pierangeli S. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006, 135:214-219.
162. Dignat-George F., Camoin-Jau L., Sabatier F., Arnoux D., Anfosso F., Bardin N., et al. Endothelial microparticles: A potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004, 91:667-673.
163. Wiener M.H., Burke M., Fried M., Yust I. Thromboagglutination by anticardiolipin antibody complex in the antiphospholipid syndrome: A possible mechanism of immune-mediated thrombosis. Thromb Res 2001, 103:193-199.
164. Emmi L., Bergamini C., Spinelli A., Liotta F., Marchione T., Caldini A., et al. Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. Ann N Y Acad Sci 1997, 823:188-200.
165. 2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants. Blood 1993, 81:1255-1262.
166. Shu F., Sugimura M., Kanayama N., Kobayashi H., Kobayashi T., Terao T. Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest 2000, 49:17-23.
167. Rand J.H., Wu X.X., Guller S., Gil J., Guha A., Scher J., et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994, 171:1566-1572.
168. Rand J.H., Wu X.X., Guller S., Scher J., Andree H.A., Lockwood C.J. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997, 177:918-923.
169. Rand J.H., Wu X.X., Lapinski R., van Heerde W.L., Reutelingsperger C.P., Chen P.P., et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004, 104:2783-2790.
170. Matsuda J., Saitoh N., Gohchi K., Gotoh M., Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994, 47:56-58.
171. Nakamura N., Ban T., Yamaji K., Yoneda Y., Wada Y. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest 1998, 101:1951-1959.
172. Hajjar K.A., Jacovina A.T., Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994, 269:21191-21197.
173. Kaczan-Bourgois D., Salles J.P., Hullin F., Fauvel J., Moisand A., Duga-Neulat I., et al. Increased content of annexin II (p36) and p11 in human placenta brush-border membrane vesicles during syncytiotrophoblast maturation and differentiation. Placenta 1996, 17:669-676.
174. Ma K., Simantov R., Zhang J.C., Silverstein R., Hajjar K.A., McCrae K.R. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275:15541-15548.
175. 2 glycoprotein I antibodies. Blood 2005, 105:1964-1969.
176. Romay-Penabad Z., Montiel-Manzano M.G., Shilagard T., Papalardo E., Vargas G., Deora A.B., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009, 114:3074-3083.
177. Raschi E., Testoni C., Bosisio D., Borghi M.O., Koike T., Mantovani A., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 101:3495-3500.
178. Satta N., Dunoyer-Geindre S., Reber G., Fish R.J., Boehlen F., Kruithof E.K., et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007, 109:1507-1514.
179. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies. Ann Rheum Dis 2007, 66:1327-1333.
180. 2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56:2687-2697.
181. 2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J Clin Invest 1998, 102:902-909.
182. 2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 2006, 4:1680-1690.
183. Andersen O.M., Benhayon D., Curran T., Willnow T.E. Differential binding of ligands to the apolipoprotein E receptor 2. Biochemistry 2004, 42:9355-9364.
184. Lutters B.C., Derksen R.H., Tekelenburg W.L., Lenting P.J., Arnout J., de Groot P.G. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003, 278:33831-33838.
185. 2-glycoprotein I for ApoER2' on platelets is located in domain V. J Biol Chem 2005, 280:36729-36736.
186. 2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006, 54:2558-2567.
187. Pennings M.T., Derksen R.H., van Lummel M., Adelmeijer J., VanHoorelbeke K., Urbanus R.T., et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: Glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 2007, 5:369-377.
188. Baglia F.A., Shrimpton C.N., Emsley J., Kitagawa K., Ruggeri Z.M., Lopez J.A., et al. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem 2004, 279:49323-49329.
189. Jankowski M., Vreys I., Wittevrongel C., Boon D., Vermylen J., Hoylaerts M.F., et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003, 101:157-162.
190. Zhou H., Wolberg A.S., Roubey R.A. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004, 104:2353-2358.
191. 2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001, 44:2870-2878.
192. Dunoyer-Geindre S., De Moerloose P., Galve-De Rochemonteix B., Reber G., Kruithof E. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2) glycoprotein 1 antibodies. Thromb Haemost 2002, 88:851-857.
193. 2 glycoprotein I antibodies. Int Immunol 2004, 16:1633-1641.
194. Vega-Ostertag M., Harris E.N., Pierangeli S.S. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004, 50:2911-2919.
195. Vega-Ostertag M., Casper K., Swerlick R., Ferrara D., Harris E.N., Pierangeli S.S. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545-1554.
196. Nakajima K., Tohyama Y., Kohsaka S., Kurihara T. Protein kinase C alpha requirement in the activation of p38 mitogen-activated protein kinase, which is linked to the induction of tumor necrosis factor alpha in lipopolysaccharide-stimulated microglia. Neurochem Int 2004, 44:205-214.
197. Lopez-Pedrera C., Buendia P., Cuadrado M.J., Siendones E., Aguirre M.A., Barbarroja N., et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54:301-311.
198. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
199. Sugiura-Ogasawara M., Nozawa K., Nakanishi T., Hattori Y., Ozaki Y. Complement as a predictor of further miscarriage in couples with recurrent miscarriages. Hum Reprod 2006, 21:2711-2714.
200. Davis W.D., Brey R.L. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992, 10:455-460.
201. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G., Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-2124.
202. 2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
203. Oku K., Atsumi T., Bohgaki M., Amengual O., Kataoka H., Horita T., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009, 68:1030-1035.
204. Sammaritano L.R., Ng S., Sobel R., Lo S.K., Simantov R., Furie R., et al. Anticardiolipin IgG subclasses: Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997, 40:1998-2006.
205. 2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome. Arthritis Rheum 1998, 41:1513-1515.